Nucleocytoplasmic Transport Assay Service

Explore nucleocytoplasmic transport (NCT) with our advanced assay service. Our nucleocytoplasmic transport assay service provides researchers with a powerful, cost-effective, and highly sensitive tool to investigate the crucial role of nuclear-cytoplasmic transport in both fundamental biology and disease pathways. For further information regarding the products and services provided, project-specific consultation, and pricing, please submit an inquiry here.

Overview of NCT

Nucleocytoplasmic transport, the vital exchange of proteins and RNA between the nucleus and cytoplasm, hinges on the functionality of the nuclear pore complex (NPC). Research increasingly indicates that disruptions in this transport process are prevalent in Amyotrophic Lateral Sclerosis (ALS), potentially resulting in the aberrant localization and impaired function of crucial proteins and RNA molecules. A striking example is the cytoplasmic aggregation of RNA-binding proteins such as TDP-43 and FUS, frequently observed in ALS patients. This accumulation may stem directly from compromised nucleocytoplasmic transport.

Nucleocytoplasmic Transport Assays

• Real-Time Dynamic Monitoring

Our system employs a highly sensitive fluorescent reporter to track protein and RNA transport rates between the nucleus and cytoplasm in real time. This allows for the detection of subtle functional abnormalities, such as transport blockages caused by ALS-related TDP-43 aggregation, providing unparalleled insight into cellular dynamics.

• Pathological Model Validation

We've validated that dipeptide repeat sequences, like poly (GR) / poly (PR), generated from C9orf72 gene mutations, effectively mimic nucleocytoplasmic transport disruptions. Our model demonstrates a significant 50% reduction in nuclear import rates, offering a reliable platform for studying ALS/FTD and related neurodegenerative diseases.

• High-Throughput Drug Screening

Integrated with an automated imaging platform, our service supports large-scale screening of nucleocytoplasmic transport regulators and potential therapeutic compounds. This capability accelerates drug discovery for neurodegenerative diseases, enabling researchers to efficiently identify and validate promising candidates.

Applications

• Disease Mechanism Research

Delve into the complexities of ALS/FTD by analyzing nucleocytoplasmic transport defects stemming from TDP-43 aggregation and RanGAP1 dysregulation.

Investigate the RNA toxicity induced by C9orf72 repeat expansions and dissect the pathological impact of RAN translation products.

• Drug Target Validation

Evaluate the efficacy of nucleocytoplasmic transport inhibitors, such as small molecules targeting CRM1, in restoring normal cellular function.

Assess the potential of gene therapy approaches, including CRISPR editing, to correct nucleocytoplasmic transport abnormalities.

We offer researchers a streamlined, cost-effective, and highly sensitive platform to investigate the critical role of nucleocytoplasmic transport in both fundamental biological processes and disease pathogenesis. Whether your work focuses on basic discovery or translational applications, we are eager to collaborate with you to drive scientific advancement. Contact us today for tailored experimental solutions designed to meet your specific research needs.

Reference

1. Vanneste, Joni, and Ludo Van Den Bosch. "The role of nucleocytoplasmic transport defects in amyotrophic lateral sclerosis." International Journal of Molecular Sciences 22.22 (2021): 12175. Distributed under Open Access license CC BY 4.0, without modification.